Skip to content

A clinical study of the relationship between SLC12A5, HOXB8, KIFC1 gene polymorphism and colorectal cancer chemotherapy sensitivity

A clinical study of the relationship between SLC12A5, HOXB8, KIFC1 gene polymorphism and colorectal cancer chemotherapy sensitivity

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043212
Enrollment
Unknown
Registered
2021-02-08
Start date
2021-02-08
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Chemotherapy observation group:Nil
Non Chemotherapy observation group:Nil

Sponsors

Shenzhen Second People Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-75 years; 2) Both male and female; 3) Colorectal cancer (CRC) was confirmed by pathology and clinical examination; 4) CRC at any T / N stage with M0 stage; 5) Those case with CRC will be treated by using chemotherapy regimen including fluorouracil, oxaliplatin and irinotecan; 6) KPS score >= 60; 7) The expected survival time was more than 6 months; 8) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Colorectal cancer patients with distant metastasis; 2) Patients with CRC have chemotherapy history or undergoing chemotherapy; 3) Patients with multiple primary tumors; 4) The estimated survival time was less than 6 months; 5) Cachexia, malnutrition and failure of important organs; 6) Pregnant or lactating women; 7) Severe cardiopulmonary functional insufficiency; 8) Using other experimental drugs or participating in other clinical trials at the same time; 9) Any clinically relevant disease that may affect study participation and / or study results; 10) Drug allergy; 11) Patients with mental disorders and Alzheimer's disease; 12) Patients who the researchers believe are unwilling or unable to follow the study protocol.

Design outcomes

Primary

MeasureTime frame
Genetic testing;tumor burden;Immune evaluation;Survival time;

Secondary

MeasureTime frame
Toxic reaction;KPS;

Countries

China

Contacts

Public ContactZhang haitao

Shenzhen Second People Hospital

1240598463@qq.com+86 13903025325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026